[go: up one dir, main page]

GB201810290D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
GB201810290D0
GB201810290D0 GBGB1810290.5A GB201810290A GB201810290D0 GB 201810290 D0 GB201810290 D0 GB 201810290D0 GB 201810290 A GB201810290 A GB 201810290A GB 201810290 D0 GB201810290 D0 GB 201810290D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1810290.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1810290.5A priority Critical patent/GB201810290D0/en
Publication of GB201810290D0 publication Critical patent/GB201810290D0/en
Priority to EP19735375.8A priority patent/EP3810131A1/en
Priority to SG11202012765PA priority patent/SG11202012765PA/en
Priority to NZ771565A priority patent/NZ771565A/en
Priority to BR112020026314-1A priority patent/BR112020026314A2/en
Priority to MX2020013853A priority patent/MX2020013853A/en
Priority to PCT/GB2019/051761 priority patent/WO2019243841A1/en
Priority to AU2019289228A priority patent/AU2019289228B2/en
Priority to CN201980054648.8A priority patent/CN113286586A/en
Priority to CA3103920A priority patent/CA3103920C/en
Priority to US17/254,854 priority patent/US20210276952A1/en
Priority to MX2025003876A priority patent/MX2025003876A/en
Priority to IL279526A priority patent/IL279526B1/en
Priority to US17/848,156 priority patent/US11919856B2/en
Priority to US18/424,192 priority patent/US20240400513A1/en
Priority to AU2025200968A priority patent/AU2025200968A1/en
Ceased legal-status Critical Current

Links

GBGB1810290.5A 2018-06-22 2018-06-22 Novel Compounds Ceased GB201810290D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds
US17/254,854 US20210276952A1 (en) 2018-06-22 2019-06-21 Novel compounds
PCT/GB2019/051761 WO2019243841A1 (en) 2018-06-22 2019-06-21 Novel compounds
CN201980054648.8A CN113286586A (en) 2018-06-22 2019-06-21 Novel compounds
NZ771565A NZ771565A (en) 2018-06-22 2019-06-21 Novel compounds
BR112020026314-1A BR112020026314A2 (en) 2018-06-22 2019-06-21 NEW COMPOUNDS
MX2020013853A MX2020013853A (en) 2018-06-22 2019-06-21 INNOVATIVE COMPOUNDS.
EP19735375.8A EP3810131A1 (en) 2018-06-22 2019-06-21 Novel compounds
AU2019289228A AU2019289228B2 (en) 2018-06-22 2019-06-21 Novel compounds
SG11202012765PA SG11202012765PA (en) 2018-06-22 2019-06-21 Novel compounds
CA3103920A CA3103920C (en) 2018-06-22 2019-06-21 Compounds for treating alpha-1 antitrypsin-mediated diseases
MX2025003876A MX2025003876A (en) 2018-06-22 2020-12-16 Novel compounds
IL279526A IL279526B1 (en) 2018-06-22 2020-12-17 Compounds for treating alpha 1 antitrypsin mediated diseases
US17/848,156 US11919856B2 (en) 2018-06-22 2022-06-23 Compounds
US18/424,192 US20240400513A1 (en) 2018-06-22 2024-01-26 Novel compounds
AU2025200968A AU2025200968A1 (en) 2018-06-22 2025-02-12 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds

Publications (1)

Publication Number Publication Date
GB201810290D0 true GB201810290D0 (en) 2018-08-08

Family

ID=63042819

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1810290.5A Ceased GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds

Country Status (1)

Country Link
GB (1) GB201810290D0 (en)

Similar Documents

Publication Publication Date Title
IL280767A (en) Novel sulfonamideurea compounds
SG11202010907VA (en) Novel compounds
IL279526A (en) Novel compounds
GB201819083D0 (en) Novel compounds
GB201803393D0 (en) Novel compounds
GB201803394D0 (en) Novel compounds
IL282096A (en) Novel compounds
GB201813060D0 (en) Novel compounds
GB201809378D0 (en) Novel compounds
GB201813065D0 (en) Novel compounds
GB201811165D0 (en) Novel compounds
GB201821000D0 (en) Novel compounds
GB201817616D0 (en) Novel compounds
GB201816543D0 (en) Novel compounds
GB201813281D0 (en) Novel compounds
GB201813280D0 (en) Novel compounds
GB201813284D0 (en) Novel compounds
GB201813285D0 (en) Novel compounds
GB201813198D0 (en) Novel compounds
GB201813049D0 (en) Novel Compounds
GB201812225D0 (en) Novel compounds
GB201812226D0 (en) Novel compounds
GB201810983D0 (en) Novel compounds
GB201810290D0 (en) Novel Compounds
GB201807362D0 (en) Novel compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UCL BUSINESS PLC

Free format text: FORMER OWNER: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

AT Applications terminated before publication under section 16(1)